Bethesda (2021) LiverTox: clinical and research information on drug-induced liver injury [Internet]. LiverTox, 2012
Bruzzese F, Leone A, Rocco M, Carbone C, Piro G, Caraglia M, Gennaro ED, Budillon A (2011) HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT. J Cell Physiol 226:2378–2390
Chang H-H, Chiang C-P, Hung H-C, Lin C-Y, Deng Y-T, Kuo MY-P (2009) Histone deacetylase 2 expression predicts poorer prognosis in oral cancer patients. Oral Oncol 45:610–614
Chang C-C, Lin B-R, Chen S-T, Hsieh T-H, Li Y-J, Kuo MYP (2011) HDAC2 promotes cell migration/invasion abilities through HIF-1α stabilization in human oral squamous cell carcinoma. J Oral Pathol Med 40:567–575
Chi AC, Day TA, Neville BW (2015) Oral cavity and oropharyngeal squamous cell carcinoma—an update. CA Cancer J Clin 65:401–421
Frey A, Soubani AO, Adam AK, Sheng S, Pass HI, Lonardo F (2010) Nuclear, compared with combined nuclear and cytoplasmic expression of maspin, is linked in lung adenocarcinoma to reduced VEGF-A levels and in stage I, improved survival. Histopathology 54:590–597
Goulet B, Kennette W, Ablack A, Postenka CO, Hague MN, Mymryk JS, Tuck AB, Giguère V, Chambers AF, Lewis JD (2011) Nuclear localization of maspin is essential for its inhibition of tumor growth and metastasis. Lab Investig 91:1181–1187
Kasamon YL, Price LSL, Okusanya OO, Richardson NC, Li R-J, Ma L, Wu Y-T, Theoret M, Pazdur R, Gormley NJ (2021) FDA approval summary: selinexor for relapsed or refractory diffuse large B-cell lymphoma. Oncologist 26:879–886
Kumar B, Yadav A, Lang JC, Teknos TN, Kumar P (2015) Suberoylanilide hydroxamic acid (SAHA) reverses chemoresistance in head and neck cancer cells by targeting cancer stem cells via the downregulation of nanog. Genes Cancer 6:169–181
Li X, Yin S, Meng Y, Sakr W, Sheng S (2006) Endogenous inhibition of histone deacetylase 1 by tumor-suppressive maspin. Cancer Res 66:9323–9329
Longhi MT, Silva LE, Pereira M, Magalhães M, Reina J, Vitorino FN, Gumbiner BM, Da Cunha JP, Cella N (2021) PI3K-AKT, JAK2-STAT3 pathways and cell–cell contact regulate maspin subcellular localization. Cell Commun Signal 19:86
Mărăşescu FIIC, Marasescu PC, Matei M, Florescu AM, Margaritescu C, Petrescu SMS, Dumitrescu CI (2018) Epidemiological and histopathological aspects of tongue squamous cell carcinomas-retrospective study. Curr Health Sci J 44:211–224
PubMed PubMed Central Google Scholar
Marioni G, Blandamura S, Giacomelli L, Calgaro N, Segato P, Leo G, Fischetto D, Staffieri A, De Filippis C (2010) Nuclear expression of maspin is associated with a lower recurrence rate and a longer disease-free interval after surgery for squamous cell carcinoma of the larynx. Histopathology 46:576–582
Marra A, Violati M, Broggio F, Codecà C, Blasi M, Luciani A, Zonato S, Rabbiosi D, Moneghini L, Saibene A, Maccari A, Felisati G, Ferrari D (2019) Long-term disease-free survival in surgically-resected oral tongue cancer: a 10-year retrospective study. Acta Otorhinolaryngologica Italica 39:84–91
McClure JJ, Li X, Chou CJ (2018) Advances and challenges of HDAC inhibitors in cancer therapeutics. Adv Cancer Res 138:183–211
Nakajima H (2007) A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p. Tanpakushitsu Kakusan Koso 52:1790–1791
Ng JH, Iyer NG, Tan M-H, Edgren G (2017) Changing epidemiology of oral squamous cell carcinoma of the tongue: a global study. Head Neck 39:297–304
Nosaka K, Horie Y, Shiomi T, Itamochi H, Oishi T, Shimada M, Sato S, Sakabe T, Harada T, Umekita Y (2015) Cytoplasmic maspin expression correlates with poor prognosis of patients with adenocarcinoma of the uterine cervix. Yonago Acta Med 58:151–156
CAS PubMed PubMed Central Google Scholar
Richard S, Jagannath S (2022) Targeting nuclear export proteins in multiple myeloma therapy. BioDrugs 36:13–25
Rodriguez CP, Wu QV, Voutsinas J, Fromm JR, Jiang X, Pillarisetty VG, Lee SM, Santana-Davila R, Goulart B, Baik CS, Chow LQM, Eaton K, Martins R (2019) A phase II trial of pembrolizumab and vorinostat in recurrent metastatic head and neck squamous cell carcinomas and salivary gland cancer. Clin Cancer Res 26:837–845
Saenz-Ponce N, Pillay R, Long LM, d., Kashyap T, Argueta C, Landesman Y, Hazar-Rethinam M, Boros S, Panizza B, Jacquemyn M, Daelemans D, Gannon OM, Saunders NA (2019) Targeting the XPO1-dependent nuclear export of E2F7 reverses anthracycline resistance in head and neck squamous cell carcinomas. Sci Transl Med 10:eaar7223
Sajnani AK, Shah SG, Rashid M, Natu A, Gera PB, Gupta S (2021) In-silico analysis of chromatin modifiers and profiling of histone deacetylases (HDAC’s) in human oral cancer. Chonnam Med J 57:176–184
Shankar E, Pandey M, Verma S, Abbas A, Candamo M, Kanwal R, Shukla S, MacLennan GT, Gupta S (2020) Role of class I histone deacetylases in the regulation of maspin expression in prostate cancer. Mol Carcinog 59:955–966
Takagi Y, Matsuoka Y, Shiomi T, Nosaka K, Takeda C, Haruki T, Araki K, Taniguchi Y, Nakamura H, Umekita Y (2014) Cytoplasmic maspin expression is a predictor of poor prognosis in patients with lung adenocarcinoma measuring less than 3 cm. Histopathology 66:732–739
Tang S, Lian X, Jiang J, Cheng H, Guo J, Huang C, Meng H, Li X (2020) Tumor suppressive maspin-sensitized prostate cancer to drug treatment through negative regulating androgen receptor expression. Front Cell Dev Biol 8:573820
Taunton J, Hassig CA, Schreiber SL (1996) A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p. Science 272:408–411
Teknos TN, Grecula J, Agrawal A, Old MO, Ozer E, Carrau R, Kang S, Rocco J, Blakaj D, Diavolitsis V, Kumar B, Kumar P, Pan Q, Palettas M, Wei L, Baiocchi R, Savvides P (2016) A phase 1 trial of vorinostat in combination with concurrent chemoradiation therapy in the treatment of advanced staged head and neck squamous cell carcinoma. Investig New Drugs 37:702–710
Theocharis S, Klijanienko J, Giaginis C, Rodriguez J, Jouffroy T, Girod A, Alexandrou P, Sastre-Garau X (2011) Histone deacetylase-1 and -2 expression in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients survival. J Oral Pathol Med 40:706–714
Yasumatsu R, Nakashima T, Hirakawa N, Kumamoto Y, Kuratomi Y, Tomita K, Komiyama S (2001) Maspin expression in stage I and II oral tongue squamous cell carcinoma. Head Neck 23:962–966
留言 (0)